THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 1, 2015/ PRNewswire/ Amgen and its subsidiary Onyx Pharmaceuticals, Inc., today announced the results from a planned interim analysis showing that the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis for Injection in combination with low-dose dexamethasone versus Velc
A document on hospital drug purchase was released Saturday, which instructed that hospitals should only source drugs from provincial pharmaceutical procurement platforms. The "significant" document, released by the State Council General Office, will aid hospital reform, regulate medicine supply and improve state policies in this regard, according t
By a News Reporter-Staff News Editor at VerticalNews Health WASHINGTON, D.C., A good drug is hard to design: to garner FDA approval and reach consumers, it must not only effectively treat a medical condition, but it must also do so without having side effects that outweigh its benefits. Now, a group of researchers from Weill Cornell Medical Colle
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA New research indicates that hormonal intrauterine devices and contraceptive implants remain highly effective one year beyond their approved duration of use, according to a study at Washington University School of Medicine in St. Louis. The researchers are evaluating whether su
BASEL- Another month has come to a close, and here we bring you a list of new drugs that passed muster with the FDA in February. The drug is to be used in combination with letrozole, another FDA- approved product used to treat certain kinds of breast cancer in postmenopausal women. This drug is the first CDK 4/ 6 inhibitor to be approved by the FDA
By a News Reporter-Staff News Editor at Heart Disease Weekly Betta Pharmaceuticals Co., Ltd. has been issued patent number 8951959, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Wang, Yinxiang; Tan, Fenlai; Hu, Shaojing; Zhao, Xiangdong; Ma, Cunbo; Wang, Yanping; Shen, Xiaoyan;
By a News Reporter-Staff News Editor at Heart Disease Weekly INO Therapeutics LLC has been issued patent number 8951579, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventor is Baldassarre, James S.. This patent was filed on August 4, 2014 and was published online on February 10, 2015.
By a News Reporter-Staff News Editor at Heart Disease Weekly A patent by the inventor Baldassarre, James S., filed on August 7, 2014, was published online on February 10, 2015, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 8951580 is assigned to INO Therapeutics LLC. The following quote
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Investigators publish new report on Halogens. According to news reporting from Tucson, Arizona, by NewsRx journalists, research stated, "The diversity of elements among U.S. Food and Drug Administration approved pharmaceuticals is analyzed and reported, with a focus on atoms o
Baltimore s Asklepion Pharmaceuticals which counts the New Zealand breakfast cereal maker as an investor secured an acquisition agreement with New York- based Retrophin in January. Retrophin has acquired the worldwide rights to Asklepion s colic acid treatment for a deadly genetic liver defect, provided the drug receives US Food and Dru
By a News Reporter-Staff News Editor at VerticalNews Science DALLAS- The common practice of excluding patients with a prior cancer diagnosis from lung cancer clinical trials may not be justified, according to a study by researchers from UT Southwestern Medical Center. Having previously had cancer did not impact clinical outcomes in advanced lung
By a News Reporter-Staff News Editor at VerticalNews Health& Science- An RTP-based pharmaceutical company with roots at the University of North Carolina at Chapel Hill has received $33 million in Series B venture capital funding to develop more effective and less toxic methods to treat patients with cancer. The Series B syndicate is led by Eshelm
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell...
Aegerion Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its alliance with the National Organization for Rare Disorders, Rare Diseases Europe and Canadian Organization of Rare Disorders, and The Global Genes...
Speaking before the House Labor, Health and Social Services Committee, he said it takes tens of million dollars and an average of eight to 10 years for a drug to work its way through the FDA approval process. Since people with terminal illnesses don't have the luxury of waiting for those drugs to be approved, Burns said SF 3 would instead make it l
Stephen Nicholls, an international HDL expert, will collaborate with Cerenis and that a highly knowledgeable cardiologist such as Dr. Renee Benghozi has become our new CMO. " Stephen Nicholls added: "I'm particularly enthusiastic about collaborating with Cerenis Therapeutics for the future Phase II CARAT clinical study of CER-001.
-Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced that Application No. 13/ 551,455, an application relating its DETERx technology platform, was allowed for issuance as a new patent by the U.S.
Cytori Therapeutics reported that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion toward Cytori's application for an orphan drug designation for the new Scleroderma therapeutic ECCS-50, which contains adipose tissue-derived stromal vascular fraction cells derived from Cytori's proprietary...
Endocyte, Inc., a biopharmaceutical company and leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data from ongoing phase 1 trials of Endocyte's SMDCs EC1456 and EC1169 will be presented at the 13 th International Congress o
Eagle Pharmaceuticals confirmed that the U.S. Food and Drug Administration has granted seven years of market exclusivity in the U.S. to Ryanodex for Injectable Suspension for the treatment of malignant hyperthermia. According to a release from the company, Ryanodex was designated an orphan drug in August 2013 and was approved by the FDA in July 201
Actavis, Irish specialty pharmaceutical firm entered an abbreviated new drug application to the US Food and Drug Administration want approval to market Budesonide Extended-release Tablets, 9 mg. Earlier in February 2015, Santarus and Cosmo Technologies filed a lawsuit, under provisions of the Hatch-Waxman Act, against Actavis in the US District Cou
Takeda Pharmaceutical Company Limited and Otsuka Pharmaceutical Company, Limited announced today that TAKECAB 10 mg and TAKECAB 20 mg, discovered by Takeda for the treatment of acid-related diseases, is now available in Japan. Takeda and Otsuka executed an agreement at the end of March 2014 to co-promote TAKECAB in Japan. From diagnosis through to
Pfizer reported positive top-line results of a Phase 2 study of TRUMENBA co-administered with FDA- approved, routine meningococcal and single-dose tetanus, diptheria and pertussis vaccines in more than 2,600 healthy individuals 10 through 12 years of age. According to a company release, the study met its co-primary immunogenicity objectives regardi
By a News Reporter-Staff News Editor at Journal of Transportation According to news reporting originating from Washington, D.C., by VerticalNews journalists, a U.S. Securities and Exchange Commission filing by Regen Biopharma Inc. was posted on February 6, 2015. The SEC file number is 0001607062-15-000045.. A U.S. Securities and Exchange Commissi
Dr. Gilman most recently served as the Executive Vice President, Research& Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck& Co.. Dr. Gilman is well-versed in the research and development of novel compounds addressing highly drug resistant and invasive pathogens, and his experience will prove invalua